Bayer Continues Pursuit Of Aspirin Primary MI Prevention Labeling
This article was originally published in The Tan Sheet
Executive Summary
Bayer is seeking FDA's input on how it can expand professional labeling for aspirin to include a primary myocardial infarction prevention indication